TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts have a consensus “Hold” rating on TransMedics Group, with six buys, six holds and one sell among 13 analysts. The average 12-month price target is $124.18.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but EPS of $0.44 missed the $0.50 consensus forecast.
• The stock opened at $88.58, down 1.2%, and remains well below its 52-week high of $156.00; institutional investors own approximately 99.67% of outstanding shares.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been given a consensus rating of "Hold" by the thirteen analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $124.1818.

A number of equities analysts have recently issued reports on TMDX shares. Oppenheimer lowered shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 6th. Piper Sandler reiterated an "overweight" rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Needham & Company LLC decreased their price target on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. TD Cowen reissued a "buy" rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Wednesday, July 1st. Finally, Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, June 18th.

TransMedics Group Stock Down 1.2%

Shares of NASDAQ TMDX opened at $88.58 on Friday. The stock has a market cap of $3.06 billion, a PE ratio of 22.77 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The business has a 50-day moving average price of $75.65 and a 200 day moving average price of $96.95.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to analysts' expectations of $184.00 million. During the same quarter in the prior year, the business earned $0.92 EPS. The company's quarterly revenue was up 20.7% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group will post 1.47 earnings per share for the current year.

Insider Activity

In related news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TMDX. Silvant Capital Management LLC acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $26,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of TransMedics Group during the third quarter worth $29,000. North Star Investment Management Corp. purchased a new position in TransMedics Group in the 1st quarter valued at $30,000. Ascentis Independent Advisors purchased a new position in TransMedics Group in the 1st quarter valued at $30,000. Finally, Allworth Financial LP increased its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after buying an additional 113 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source